Pfizer Inc

• 2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market - Patients can already access the first GLP-1 obesity pill from Novo Nordisk, and a rival oral drug from Eli Lilly is slated for U.S. approval later this year.
• Nine of the largest pharma companies ink deals with Trump to lower drug prices - President Donald Trump has pushed to lower drug prices for Americans, which are on average nearly three times higher than overseas.
• Wall Street banked on a flurry of deals under Trump in 2025. It wasn't that simple - Dealmakers expected a flood of M&A to take place in 2025 following the election of President Trump. The number of transactions didn't live up to the hype.